Vascular Biogenics's Total Assets for the quarter that ended in Jun. 2023 was $24.65 Mil.
During the past 12 months, Vascular Biogenics's average Total Assets Growth Rate was -96.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -10.50% per year.
During the past 5 years, the average Total Assets Growth Rate was -2.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 32.90% per year.
During the past 11 years, Vascular Biogenics's highest 3-Year average Total Assets Growth Rate was 100.70%. The lowest was -10.50%. And the median was 23.30%.
The historical data trend for Vascular Biogenics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Vascular Biogenics's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vascular Biogenics (NAS:VBLT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Vascular Biogenics's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Vascular Biogenics Total Assets Related Terms
Thank you for viewing the detailed overview of Vascular Biogenics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vascular Biogenics (Vascular Biogenics) Business Description
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VBLT has been successfully added to your 